One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels
UniQure's Stock Is Trading Higher As FDA Lifts Clinical Hold On Its Hemophilia B Gene Therapy Program
Newly Launched Centessa Pharmaceuticals Plans $100M Debut On NASDAQ
Freeline Therapeutics To Start FLT180a Dose Confirmation Study In Hemophilia B By 2021 End